News
Former VP of Pfizer Joins EnBIO’s Board of Management
Cork, Ireland- October 8th, 2007: EnBIO Ltd, today announced the appointment of Paddy Caffrey as chairman of the EnBIO board.
EnBIO Ltd, develops leading edge surface modication technologies that enables drug eluting properties on metallic surfaces across a multitude of medical sectors.
Paddy Caffrey, former VP and managing director of Pfizer Ireland Pharmaceuticals, has over 30 years experience in this industry. He was the president of the Institution of Engineers of Ireland in 2004/2005. He is a former chairman of the Irish branch of ISPE, the international society of pharmaceutical engineering, also a former Chairman of PharmaChemical Ireland. He was a member of IBEC’s national executive council and former Chairman of the IBEC Cork Region. He is currently Chairman of the Governing body of the Cork Institute of Technology as well as board member of several Irish companies.
Commenting on the announcement, Dan Philpott CEO, EnBIO said “We are delighted to welcome Paddy to EnBIO’s management board, his wealth of experience and extensive customer network, will propel the company to its next level of success”
Paddy said “EnBIO is a exciting highly innovative company reflective of Ireland’s knowledge economy. EnBIO’s technology’s platforms promise to provide deliver alternative drug delivery capabilities to the medical sector. I look forward to contributing to the company’s future success”
EnBIO’s products are based on patent pending surface modification techniques which can be applied to variety of surfaces widely used in medical devices but also in the aeronautical, electronic and food industries.
In its research pipeline, the company has an active research programme in partnership with the University of Ulster to commercialise the multitude of application for the company’s proprietary technology.
About EnBIO
EnBIO is an Irish owned company whose proprietary breakthrough technology delivers a step-change in drug eluting capabilities across a multitude of medical device sectors. EnBIO’s area of specialization is in the surface modification of medical devices. Its recent development of novel technology that enables low-cost, room temperature manufacture on bare metal surfaces presents a market-disruptive opportunity Using its proprietary technology EnBIO can apply drug eluting capabilities across a multitude of medical device sectors. The company’s initial focus is the orthopaedic and Cardiac Rhythm Management markets. These technologies will benefit the implant patient by reducing trauma and recovery time following surgical procedure, while enhancing the functionality and long-term viability of the implant itself
site design: